PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026Advances in Therapy0 citationsOpen Access

Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing Surveillance

ASAkemi SebataTNTakako NagaoTMTomoko Matsukawa

Key Points

  • The aim was to evaluate the long-term safety and effectiveness of dolutegravir and its combinations in Japanese individuals living with HIV.
  • Conducted a 10-year post-marketing surveillance study
  • Analyzed safety and effectiveness profiles of dolutegravir and combinations
  • Monitored for new safety concerns
  • No new safety concerns were identified during the surveillance period
  • Continued support for the established safety profiles of the drugs
  • Reinforcement of their role as key therapeutic options in clinical practice

Abstract

This 10-year post-marketing surveillance confirms the long-term safety and effectiveness of single-agent DTG and DTG/ABC/3TC in Japanese PLHIV. No new safety concerns emerged over the 10-year surveillance period, further supporting their established safety profiles and reinforcing their continued role as key therapeutic options in routine clinical practice.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sebata et al. (2026) studied this question.

synapsesocial.com/papers/69ccb74216edfba7beb89184https://doi.org/10.1007/s12325-026-03544-0
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan2021 · 17 citations
  2. 2Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia2024 · 6 citations
  3. 3Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel2024 · 267 citations
  4. 4AIDS at 40th: The progress of HIV treatment in Japan2022 · 9 citations
  5. 5Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial2013 · 375 citations